Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-094-0 | CAS number: 68515-51-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1990-08-30 to 1990-12-03
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study, read-across
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- 1,2-Benzenedicarboxylic acid, di-C8-10-alkyl esters
- EC Number:
- 275-809-7
- EC Name:
- 1,2-Benzenedicarboxylic acid, di-C8-10-alkyl esters
- Cas Number:
- 71662-46-9
- IUPAC Name:
- 71662-46-9
- Details on test material:
- - Name of test material (as cited in study report): Phthalic acid, di-n-octyl, n-decyl ester
- Substance type: product
- Physical state: liquid
- Storage condition of test material: stored in the dark at room temperature
Other: Chemical names: di-n-C8-C10-alkylphthalate; octyl-decylphthalate
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: obtained from human blood
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI 1640 tissue culture medium
- Properly maintained: not applicable
- Periodically checked for Mycoplasma contamination: not applicable
- Periodically checked for karyotype stability: not applicable
- Periodically "cleansed" against high spontaneous background: not applicable - Additional strain / cell type characteristics:
- other: stable karyotype with 46 chromosomes, stimulated to cell division in vitro by addition of the mitogen PHA (phytohaemogglutinin)
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver S9 of Arochlor 1254 induced Sprague-Dawley rats
- Test concentrations with justification for top dose:
- Range finding: 0.4, 0.8, 1.6, 3.2, 6.3, 12.5, 25, 50, 100, 200 µg/mL
Dose levels selected for metaphase analysis in the main tests: 25, 100 and 200 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: ethanol
- Justification for choice of solvent/vehicle: The test substance was miscible with ethanol at 500 mg/mL, all final concentrations greater than 200 µg/mL were unmiscible with the tissue culture medium. 200 µg/mL was, therefore, regarded as the maxium achievable concentration.
Controlsopen allclose all
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- ethanol, 1% in tissue culture medium
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- without metabolic activation
Migrated to IUCLID6: 750 µg/mL; dissolved in dimethylsulphoxide
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- ethanol, 1% in tissue culture medium
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation
Migrated to IUCLID6: 15 µg/mL, dissolved in sterile distilled water
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
Cells were suspended at a concentation of 1x10E6 cells/mL in culture medium with addition of 20 % foetal bovine serum and 5 mL aliquots were incubated in multiwell plates at 37°C with 5 % CO2 for approx. 48 hours. The cells were treated with different test substance concentrations or positive controls and for tests with metabolic activation system the rat liver S9 mix were added. Three hours after dosing the cultures containing metabolic activation were resuspended with fresh medium and incubated for further 21 hours. 22 hours after treatment with test item mitotic activity was arrested by addition of colchicine (final concentration 0.25 µL/mL). After 2 hours cells were removed from the culture dishes, incubated under hypotonic conditions for 10 minutes. The cell suspensions were centrifuged and the cell pellets fixed by addition of fresh methanol/glacial (3:1 v/v). Prior to slide preparation the pellets were aspirated through a hypodermic needle, then centrifugated and finally resuspended in a small volume of fixative. The cells suspensions were dropped onto each of five slides where they allowed to air-dry and stained afterwards with Giemsa solution, dried and mounted in DPX. The prepared slights were examined by light microscopy.
DURATION
- Preincubation period: not applicable
- Exposure duration: 3 h in the presence of S9 mix; 24 h in the absence of S9 mix
- Expression time (cells in growth medium): not applicable
- Selection time (if incubation with a selection agent): not applicable
- Fixation time (start of exposure up to fixation or harvest of cells): 24 h
SELECTION AGENT (mutation assays): not applicable
SPINDLE INHIBITOR (cytogenetic assays): Colchicine (final concentration 0.25 µL/mL)
STAIN (for cytogenetic assays): Giemsa solution
NUMBER OF REPLICATIONS: two cultures per dose level, four replicates for control
NUMBER OF CELLS EVALUATED: 200 metaphases per dose level (with normal a maximum of 25 from each slide)
DETERMINATION OF CYTOTOXICITY
- Method: The proportion of metaphase figures were examined. From these results the dose level causing a decrease in mitotic index of 50 - 80 % of the solvent control value or, if there was no decrease, the maximum achievable (or advisable) concentration was used as the highest dose level for the metaphase analysis. The intermediate and low doses were 50 % and 12.5 % of the highest concentration.
OTHER EXAMINATIONS:
- Determination of polyploidy: no
- Determination of endoreplication: no
- Other: Cells were examined for the presence of the following aberrations:
Gaps (chromatid and isochromatid), breaks (chromatid and isochromatid), interchanges, dicentric chromosomes, acentric chromosomal fragments, chromosome rings, complete metaphase pulverisation
OTHER: no repeat experiment performed - Evaluation criteria:
- not specified
- Statistics:
- Statistical analysis used was Fisher's test.
Results and discussion
Test resultsopen allclose all
- Species / strain:
- lymphocytes: human peripheral blood lymphocytes
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: human peripheral blood lymphocytes
- Metabolic activation:
- with
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: no data
- Effects of osmolality: no data
- Evaporation from medium: not applicable
- Water solubility: no data
- Precipitation: All final concentrations greater than 200 µg/mL were immiscible with the tissue culture medium
- Other confounding effects: none
RANGE-FINDING/SCREENING STUDIES: No cytotoxicity at concentrations up to 200 µg/ml in the presence and absence of metabolic activation.
COMPARISON WITH HISTORICAL CONTROL DATA: no data
ADDITIONAL INFORMATION ON CYTOTOXICITY: none
Any other information on results incl. tables
Table #1: Summary of data obtained in chromosomal aberration test
Treatment | Aberrant Cell Frequency | |||||||
Conc. [µg/mL] | S9 Mix | Mitotic index[%] | No. of CellsScored | Including Gaps | Excluding Gaps | |||
% | Judge | % | Judge | |||||
Vehicle Control | 1% Ethanol | + | 8.9 | 400 | 0.0 | - | 0.0 | - |
Test substance | 25 | + | 7.3 | 200 | 0.0 | neg. | 0.0 | neg. |
Test substance | 100 | + | 8.0 | 200 | 0.5 | neg. | 0.0 | neg. |
Test substance | 200 | + | 9.4 | 200 | 0.0 | neg. | 0 .0 | neg. |
Cyclophosphamide | 15 | + | n.d. | 151 | 15.9 | pos. *** | 15.9 | pos.*** |
Vehicle Control | 1% Ethanol | - | 8.5 | 400 | 1.5 | - | 1.5 | - |
Test substance | 25 | - | 6.3 | 200 | 2.0 | neg. | 2.0 | neg. |
Test substance | 100 | - | 8.1 | 200 | 1.0 | neg. | 1.0 | neg. |
Test substance | 200 | - | 6.0 | 200 | 1.5 | neg. | 1.5 | neg. |
Ethylmethanesulphonate | 750 | - | n.d. | 200 | 12.5 | pos. *** | 12.5 | pos.*** |
neg. = negative aberration frequency pos.*** = positive aberration frequency, statistically significant (p<0.001) n.d. = not determined
neg. = negative aberration frequency pos.*** = positive aberration frequency, statistically significant (p<0.001)
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
negative - Executive summary:
It was concluded that the structurally related substance 1,2-Benzenedicarboxylic acid, di-C8-10-alkyl esters had shown no evidence of clastogenic activity in this in-vitro cytogenetic test system.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
